ZIRCON Presentation at International Kidney Cancer Symposium 2021
8 November 2021 – Corporate Spotlight | Telix presents Phase III ZIRCON trial at the International Kidney Cancer Symposium 2021
Telix is pleased to release a poster on the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab), the Company’s investigational imaging agent for clear cell renal cell carcinoma (ccRCC) with positron emission tomography (PET), presented at the International Kidney Cancer Symposium (IKCS) 2021, organized by the Kidney Cancer Association.
The poster was presented by Dr. Allan Pantuck, Principal Investigator at the University of California, Los Angeles, one of the clinical sites for the global ZIRCON trial.
TLX250-CDx, Multi-Center Phase III Trial for PET/CT Imaging of Clear Cell Kidney Cancer
Authors: Brian Shuch1, Allan Pantuck 1, and Colin Hayward2
1Department of Urology, University of California at Los Angeles, Los Angeles, CA; 2 Telix Pharmaceuticals, Melbourne, Australia
TLX250-CDx has not received a marketing authorisation in any jurisdiction.
To download the poster presentation in PDF please click here.
For more on Telix’s investigational kidney cancer program please click here.
To return to Telix’s homepage please click here.
Telix at ANZSNM Annual Scientific Meeting 2022
9 May 2022 – Corporate Spotlight | Telix supporting and participating in Australian and New Zealand Society of Nuclear Medicine...
First Patient Dosed in Phase II Renal Cancer Theranostics Study
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 5 May 2022. Telix announces that a first patient has been dosed in...
Telix Further Strengthens European Distribution Network for Illuccix
Melbourne (Australia) and Liège (Belgium)– 22 April 2022. Telix announces agreements with Avanço and THP for the distribution of Telix’s...